• Statin Drug Warning Issued

    Posted September 8, 2015: by Bill Sardi

    The claim that the health benefits derived from cholesterol-lowering statin drugs “far out-weigh” potential harms among healthy and high-risk patients continues to be echoed throughout modern medicine. [Current Pharmaceutical Design 2015; British Medical Journal July 17, 2014]

    But now a warning has been issued by leading researchers that modern medicine re-think its broadened approach to the use of statin drugs among healthy patients.  [Daily Mail UK Sept 6, 2015]

    Only a tiny minority of subjects who take statins as a preventative medicine will live longer – studies show 0.5 per cent avoid a non-mortal heart attack or stroke by taking the drugs for five years while a significant percentage may experience serious statin drug side effects, say investigators.

    Yet statin drugs users, fearful they may experience a heart attack, keep using statin drugs.  Researchers say the risk of death from statin drug cessation is approximately 1 in 10,000.  At best, statin drugs have no effect on mortality or at best offer a one-half of 1% reduction.  Physicians are urged to advise their patients about modifiable risk factors such as diet, tobacco and alcohol use before prescribing statin drugs.  [Prescriber Sept 2015 Access requires free registration]

    Side effects attributed to statin drugs (muscle damage, diabetes, cataracts) are intentionally minimized.  Muscle aches and pains are estimated to affect 10% of statin drug users.  Researchers say most of these side effects go unreported because up to three-quarters of new statin drug users discontinue use due to side effects.

    The problem with cholesterol-lowering medications is that only a few statin users will actually experience a heart attack.  The risk of a heart attack at age 40 is 4 in 10,000 over a 10-year period; over age 60, 37 in 10,000.  Over that time span it is more likely a person will die of another cause.  [Know Your Chances]  — ©2015 Bill Sardi, Knowledge of Health Inc.

    Share

Comments are closed.